Clinical trials: Embolic Stroke of Undetermined Source
Embolic Stroke of Undetermined Source
Registry Study for the Observation of Patients With ESUS/Cryptogenic Stroke
Up to know, there is no clear diagnostic and therapeutic pathway for patients with embolic stroke of undetermined source (ESUS).
- Trial name
- Catch-up-ESUS (NCT03820375)
- Where
- Germany
- Volunteers
- 750 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Paroxysmal Nocturnal Hemoglobinuria, Embolic Stroke of Undetermined Source
Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal hematological disorder, which can cause arterial or venous thrombosis.
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria, Embolic Stroke of Undetermined Source, Transient Ischemic Attack, Cerebral Vein Thrombosis
- Trial name
- NCT03329365
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Embolic Stroke of Undetermined Source
Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause
The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO…
- Trial name
- NCT07295769
- Testing
- MEMO Patch M and MEMO Patch2
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Ischemic Stroke, Embolic Stroke of Undetermined Source
SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort…
- Conditions
- Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO), Elderly
- Trial name
- SENIOR (NCT07479147)
- Testing
- PFO closure, Medication
- Where
- 3 sites in Taiwan
- Volunteers
- 400 people
- Sponsor
- Taichung Veterans General Hospital
Embolic Stroke of Undetermined Source
Thirty Day Heart Monitoring for Detection of Atrial Fibrillation Among Cryptogenic Stroke Patients
The PROPhecy study aims to detect the presence of atrial fibrillation/flutter in patients who have suffered an embolic stroke of undetermined source (ESUS) using 30 day cardiac monitoring.
- Trial name
- PROPhecy (NCT03712865)
- Where
- Canada
- Volunteers
- 232 people
- Sponsor
- University of British Columbia
Embolic Stroke of Undetermined Source, Ischemic Stroke
Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis
A stroke is the second cause of deaths after heart attack, one of the most important causes of malfunction as far as adults are concerned and the second as for the frequency cause of dementia.
- Conditions
- Embolic Stroke of Undetermined Source, Ischemic Stroke, Atrial Fibrillation and Flutter, Myocardial Infarction
- Trial name
- NCT03377465
- Testing
- ADMA (asymmetric dimethylarginine) , NTproBNP (N-terminal pro b-type natriuretic peptide), IL-6 (Interleukin 6), Adiponectina, Leptine, Syndecan, Resistin
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medical University of Lodz
Embolic Stroke of Undetermined Source
Prediction of AF in ESUS
The aim of the proposed study is to identify predictors of covert atrial fibrillation (AF) in Embolic Stroke of Undetermined Source (ESUS) patients and develop a prognostic score for the identification of covert AF in this…
- Trial name
- AF-ESUS (NCT02766205)
- Where
- 3 sites in Greece, Switzerland
- Volunteers
- 500 people
- Sponsor
- University of Thessaly
Embolic Stroke of Undetermined Source, Ischemic Stroke
Transesophageal Echocardiography in Embolic Stroke of Undetermined Source
The ESUS concept was introduced recently to describe a non-lacunar stroke of undetermined etiology. The following etiological workup is required in this setting: head CT or MRI, 12-lead ECG, transthoracic echocardiography…
- Trial name
- ETO (NCT03107637)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Carotid Artery Disease, Symptomatic Carotid Artery Stenosis
High Coverage CARotid Stenting vs. Medical Management Alone to Prevent EmboliSm From symptomaTic Non-stenotic cARotid Disease (SyNC)
Goal is to analyse the clinical safety and efficacy of the CARESTO® heal Stent within standard clinical routine for the treatment of patients with symptomatic non-stenotic carotid disease (SyNC) and with high-risk plaque features…
- Conditions
- Carotid Artery Disease, Symptomatic Carotid Artery Stenosis, Carotid Artery Stenting, Carotid Plaque Imaging
- Trial name
- CARESTAR (NCT07166731)
- Where
- Germany
- Volunteers
- 536 people
- Sponsor
- Acandis GmbH
Embolic Stroke of Undetermined Source, Atrial Fibrillation New Onset
EMPA-ESUS. a Randomised Control Trial to Investigate the Impact of Empagliflozin on Left Atrial Function in Patients with Embolic Stroke of Undetermined Source
Atrial fibrillation (AF) is the most common heart rhythm problem in the adult population. There is a five-fold increase in stroke risk in patients with AF.
- Trial name
- EMPA-ESUS (NCT06715449)
- Testing
- Empagliflozin 10 MG
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of East Anglia
Embolic Stroke of Undetermined Source
Apixaban for Treatment of Embolic Stroke of Undetermined Source
Multicentre (national, Germany), randomized (2x2 factorial), open, parallel group, active controlled, efficacy study (phase III)
- Trial name
- ATTICUS (NCT02427126)
- Testing
- Apixaban, Aspirin
- Where
- 16 sites in Germany
- Volunteers
- 352 people
- Sponsor
- University Hospital Tuebingen
Stroke, Cardiac Disease
Multifactorial Risk Stratification in Stroke Patients With Cardiac Disease
Prospective registry for multifactorial risk factor assessment, enrolling consecutive ischemic stroke/transient ischemic attack patients with structural, inflammatory, or arrhythmogenic cardiac disease, who are admitted to our…
- Trial name
- NCT04352790
- Volunteers
- 878 people
- Sponsor
- University Hospital Tuebingen